Lin Chih-Yin, Yao Chun-An
Department of Neurology, Chang Gung Memorial Hospital, Linkou 333, Taiwan.
Department of Dermatology, Cathay General Hospital, Taipei, Taiwan.
Infect Drug Resist. 2020 Jun 11;13:1735-1741. doi: 10.2147/IDR.S256773. eCollection 2020.
The outbreak of coronavirus disease 2019 (COVID-19) pandemic has already caused a huge burden to the global healthcare system, with the death toll reached tens of thousands. Although some antiviral agents were identified and used to inhibit viral replication, the management of cytokine storm is also a critical issue. In this article, we reviewed the literature on drug candidates for severe acute respiratory syndrome (SARS-CoV-1) and provided a brief overview of a class of drugs that exert antiviral and anti-inflammatory effects. These molecules mitigated inflammatory cytokine cascades induced by viral infections via Nrf2 activating capacity and might have additional anti-fibrotic and anti-remodeling properties. Besides, their effects on the regulation of scavenger receptors expression by macrophages may offer some benefits to the pulmonary antibacterial defense system after viral infection. The potential roles of these agents assessed on the basis of the pathophysiology of viral pneumonia and acute respiratory distress syndrome were also discussed. Further research is needed to ascertain whether Nrf2 activators are useful in the management of viral pneumonia.
2019年冠状病毒病（COVID-19）大流行的爆发已经给全球医疗系统带来了巨大负担，死亡人数已达数万人。尽管已确定并使用了一些抗病毒药物来抑制病毒复制，但细胞因子风暴的管理也是一个关键问题。在本文中，我们回顾了关于严重急性呼吸综合征（SARS-CoV-1）候选药物的文献，并简要概述了一类具有抗病毒和抗炎作用的药物。这些分子通过激活Nrf2减轻了病毒感染诱导的炎性细胞因子级联反应，并且可能具有额外的抗纤维化和抗重塑特性。此外，它们对巨噬细胞清道夫受体表达的调节作用可能会给病毒感染后的肺部抗菌防御系统带来一些益处。我们还讨论了基于病毒性肺炎和急性呼吸窘迫综合征的病理生理学评估这些药物的潜在作用。需要进一步研究以确定Nrf2激活剂是否对病毒性肺炎的治疗有用。
